HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today reported fourth quarter and full year ended December 31, 2011 financial results.
Fourth Quarter 2011 Results
Total revenues increased to $158.6 million, compared to $99.1 million in the prior year period primarily due to higher sales of generic Adderall XR®.
